Natco Pharma gets EIR for its Mekaguda API facility

On Tuesday, Natco Pharma Limited informed the bourses about the successful closure of inspection at its Andhra facility, with the receipt of an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA).

The inspection was conducted at its Active Pharmaceutical Ingredient (API) facility in Mekaguda Village, near Hyderabad, India, which was conducted during the period August 5-9, 2019.

Last week, the company had informed that after the end of inspection, the facility had received six observations mostly procedural in nature. The company had stated that none of the observations were related to data integrity and would be addressed within short period of time.

In the month of August, the company had received EIR from USFDA for the inspection conducted at its drug formulations facility in Kothur Village, Telangana during the period May 30 to June 5, 2019. Also, its API facility in Chennai, which was inspected during July 8-12, was successfully completed with zero observations.

On Tuesday, the stock of Natco Pharma opened at Rs. 585.90. During the morning trading session, it surged by 2.9 per cent to Rs. 598.15.